Products Affected - Description

• • Albuterol Sulfate inhalation solution, Akorn, 0.5% 5 mg/mL, 20 mL bottle, 1 count, NDC 50383-0741-20 - discontinued

Reason for the Shortage

• • Akorn ceased operations in February 2023.
  • Mylan (Viatris) has albuterol sulfate inhalation solution available.
  • Nephron Pharmaceuticals has albuterol sulfate inhalation solution available.
  • Ritedose has albuterol sulfate inhalation solution available.
  • Sun Pharma has albuterol sulfate inhalation solution available.

Available Products

• • Albuterol Sulfate inhalation solution, Mylan (Viatris), 0.083% 3 mL (2.5 mg), Unit-of-use vial, 25 vials per foil pouch, 25 count, NDC 00378-8270-52
  • Albuterol Sulfate inhalation solution, Mylan (Viatris), 0.083% 3 mL (2.5 mg), Unit-of-use vial, 30 vials per foil pouch, 30 count, NDC 00378-8270-93
  • Albuterol Sulfate inhalation solution, Mylan (Viatris), 0.083% 3 mL (2.5 mg), Unit-of-use vial, 1 vial per foil pouch 30 count, NDC 00378-8270-55
  • Albuterol Sulfate inhalation solution, Mylan (Viatris), 0.083% 3 mL (2.5 mg), Unit-of-use vial, 30 vials per foil pouch 60 count, NDC 00378-8270-91
  • Albuterol Sulfate inhalation solution, Nephron Pharmaceuticals Corporation, 0.5% 2.5 mg/0.5 mL, Unit-of-use vial, 30 count, NDC 00487-9901-30
  • Albuterol Sulfate inhalation solution, Nephron Pharmaceuticals Corporation, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 25 count, NDC 00487-9501-25
  • Albuterol Sulfate inhalation solution, Nephron Pharmaceuticals Corporation, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 1 vial per foil pouch, 30 count, NDC 00487-9501-01
  • Albuterol Sulfate inhalation solution, Nephron Pharmaceuticals Corporation, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 30 count, NDC 00487-9501-03
  • Albuterol Sulfate inhalation solution, Ritedose, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 25 vials per foil pouch, 25 count, NDC 76204-0200-25
  • Albuterol Sulfate inhalation solution, Ritedose, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 1 vial per foil pouch, 30 count, NDC 76204-0200-01
  • Albuterol Sulfate inhalation solution, Ritedose, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 30 vials per foil pouch, 30 count, NDC 76204-0200-30
  • Albuterol Sulfate inhalation solution, Ritedose, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 2 pouches of 30 vials, 60 count, NDC 76204-0200-60
  • Albuterol Sulfate inhalation solution, Sun Pharma, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 5 vials per foil pouch, 30 count, NDC 47335-0703-52
  • Albuterol Sulfate inhalation solution, Sun Pharma, 0.083% 3 mL (2.5 mg), Unit-of-use vial, 5 vials per foil pouch, 60 count, NDC 47335-0703-54

• • Levalbuterol hydrochloride inhalation solution may be used as an alternative to albuterol inhalation solution. Most levalbuterol inhalation solution presentations are currently available.
  • Levalbuterol solution for nebulization is labeled for the management of acute bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.[1]
  • In children 6-11 years of age, the initial dose is 0.31 mg nebulized three times daily. Routine dosing should not exceed 0.63 mg three times daily.[1]
  • In adults or adolescents 12 years of age or older, the initial dose is 0.63 mg nebulized three times daily (every 6 to 8 hours). Patients 12 years of age and older with more severe asthma or those not responding adequately to the 0.63 mg dose may benefit from 1.25 mg nebulized three times a day.[1]

• 1. Lexicomp online, AHFS Drug Information (Adult and Pediatric). Bethesda, MD: American Society of Health-System Pharmacists; 2022.